Month: April 2015

Being thin and of normal weight doesn't necessarily mean one is healthy. … Which is the best way to lose weight – physical activity or dietary plan?
Go to Source

COPENHAGEN (Reuters) – Novo Nordisk said on Wednesday it had launched its Saxenda obesity drug in the United States, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker. Novo Nordisk said it expected to launch the drug in other markets later this year. The company has said before it expected sales from the drug to amount to $1 billion a year. (Reporting by Sabina Zawadzki; editing by Teis Jensen)
Go to Source

Israeli turnaround specialist Erez Vigodman, the chief executive of Teva Pharmaceutical Industries , is looking to pull off the ultimate transformation with the biggest deal in Israel's corporate history. His unsolicited $40 billion offer for smaller generic drug rival Mylan Inc is Vigodman's attempt to turn Teva into a global drug powerhouse with a $100 billion market valuation, a far cry from its start as a small wholesale drug business in Jerusalem more than a century ago. Despite having no pharmaceutical experience, Vigodman, 55, was hired by Teva in February last year after he had turned around MA Industries, an Israeli agro-chemicals group. At MA Industries, today called Adama, Vigodman restored profitability and invested in growth areas.

Go to Source

Below are major deals by Teva, Israel’s largest company and the world’s biggest maker of generic drugs. * In March 2015 it said it would buy U.S. neurology drug company Auspex Pharmaceuticals for an equity value of $3.5 billion, a move to boost its portfolio of treatments for the central nervous system. * In 2011, Teva bought U.S. specialty drugmaker Cephalon for $6.8 billion, acquiring pain, sleep and cancer drugs as well as 57 percent of Japan’s Taiyo Pharmaceutical for $460 million. * In 2008, Teva bought Barr Pharmaceuticals in the United States and its European subsidiary Pliva for $7.5 billion.
Go to Source

By Ian Simpson WASHINGTON (Reuters) – A U.S. federal judge begins hearings on Wednesday on whether would-be presidential assassin John Hinckley Jr. could get more time outside the mental hospital where he has lived since shooting Ronald Reagan in 1981. Hinckley, 59, has been allowed since December 2013 to leave Washington's St. Elizabeths Hospital for 17 days a month to stay with his mother in Williamsburg, Virginia. Hinckley shot Reagan and three others, including White House press secretary James Brady, in an attempt to impress actress Jodie Foster, with whom he was obsessed. The hearing before U.S. District Judge Paul Friedman will determine whether the terms of Hinckley's confinement should be changed, and could last months before a decision is made.

Go to Source

By Sarah N. Lynch WASHINGTON (Reuters) – Nearly 80 percent of American companies surveyed by two human rights groups failed to meet a U.S. rule requiring they monitor whether their products contain minerals from war-torn Africa. The joint report by Amnesty International and Global Witness is the first by outside groups to analyze so-called "conflict mineral" disclosures by U.S. public companies complying with the Securities and Exchange Commission rule. “The conflict minerals law is an opportunity to clean up global mineral supply chains. The survey of 100 companies found that 79 percent of them failed to meet all the minimum requirements, and 41 percent to show they had policies to identify risks in their supply chain.

Go to Source

It has been called a “fixation on righteous eating “or an unnatural obsession with maintaining a healthy diet. Orthorexia, according to the National …
Go to Source